RBC Capital lowered the firm’s price target on DexCom (DXCM) to $115 from $120 but keeps an Outperform rating on the shares. The firm’s Q3 revenue beat was aided by record new patient starts, though its earnings was impacted by lower gross margins, the analyst tells investors in a research note. DexCom momentum is building into year-end, and the firm also has a “clear line of sight” to at least 15% y/y growth in 2025, RBC added.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Morning Movers: Capri sinks after judge blocks planned takeover by Tapestry
- DexCom price target lowered to $99 from $115 at Raymond James
- DexCom price target lowered to $105 from $115 at Oppenheimer
- DexCom price target raised to $86 from $82 at Bernstein
- DexCom Earnings: DXCM Stock Plunges 16% Despite Beating Q3 Estimates